SPMC Launches Montelukast and Methylprednisolone Tablets to Strengthen Respiratory Care

State Pharmaceuticals Manufacturing Corporation (SPMC), based in Sri Lanka, has declared the launch of two medicines: Montelukast Tablets IP 10 mg and Methylprednisolone Tablets USP 4 mg. These are the new products that are developed to help patients with respiratory and inflammatory conditions with safe, effective, and affordable treatment options. Introduced as part of the international quality standards, the introduction is a significant step towards enhancing the domestic pharmaceutical manufacturing capacity of Sri Lanka, coupled with assisting in the accessibility of the necessary medication.

Improving Respiratory and Allergic Conditions Treatment

Montelukast IP 10 mg Tablets contain the active pharmaceutical ingredient that is an antagonist of the leukotriene receptor and the active ingredient, Montelukast. It is possible to define leukotrienes as natural products synthesized in the body, which lead to the inflammation of airways and the production of mucus, especially in asthmatic and allergic people. Inhibiting the leukotrienes, Montelukast reduces the airway inflammation and makes breathing easy without provoking such signs of this condition as wheezing, dyspnea, and allergies.

According to Precedence Research, the Montelukast Sodium Market size was calculated at USD 1.07 billion in 2025 and is predicted to increase from USD 1.13 billion in 2026 to approximately USD 1.88 billion by 2035, expanding at a CAGR of 5.80% from 2026 to 2035, due to the increase in cases of asthma and allergies.

Industry Impact and Outlook

The launch of these medicines underscores SPMC's determination to make sure that high-quality, affordable pharmaceuticals are available in the country. Production of these drugs will enable Sri Lanka to reduce its dependency on imported medicine, strengthen its supply chain, and secure unmatched access to the primary treatments. It is also an indicator of a broader movement around the world where governments and pharmaceutical organizations in the public sector have been taking initiatives towards manufacturing activities within the country in an effort to improve the health care systems.

Adding Montelukast and Methylprednisolone pills to the healthcare industry of Sri Lanka is going to be a step in the right direction towards the advancement of the local healthcare sector of the country, allowing the latter to increase the autonomy of the former in terms of taking medication.